12:00 AM EDT, 06/30/2026 (MT Newswires) -- Abivax (ABVX.PA) said Obefazimod, its investigative treatment for ulcerative colitis, exhibited meaningful clinical benefits in a supplemental portion of its phase 3 maintenance program. The treatment is an oral miR-124 enhancer that was tested in patients who did not achieve clinical response following induction treatment or who experienced disease relapse during the re-randomized maintenance trial, according to a Monday release. The topline results were observed in the maintenance program for patients with moderate to severely active ulcerative colitis.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.